Cargando…

A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors

PURPOSE: The purpose of the study was to evaluate safety and determine the maximum tolerated dose (MTD) of MEDI-575, a fully human monoclonal antibody that selectively binds to platelet-derived growth factor receptor-α (PDGFRα), in patients with advanced solid tumors. METHODS: This phase I multicent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becerra, Carlos R., Conkling, Paul, Vogelzang, Nicholas, Wu, Hilary, Hong, Shengyan, Narwal, Rajesh, Liang, Meina, Tavakkoli, Fatemeh, Pandya, Naimish
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209236/ https://www.ncbi.nlm.nih.gov/pubmed/25149088 http://dx.doi.org/10.1007/s00280-014-2567-9

Ejemplares similares

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
por: Goldberg, Avram, et al.
Publicado: (2014)

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
por: Schiopu, Elena, et al.
Publicado: (2016)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
por: Naing, Aung, et al.
Publicado: (2019)

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
por: Yang, Hui, et al.
Publicado: (2018)

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
por: Pegram, Mark D., et al.
Publicado: (2021)

Mozart Streichquartette KV421 & 575
por: Mozart, Wolfgang Amadeus, 1756-1791

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
por: Song, Yan, et al.
Publicado: (2021)

Medi-wiki worries?
por: Mason, Fred
Publicado: (2009)

MediNet: transfer learning approach with MediNet medical visual database
por: Reis, Hatice Catal, et al.
Publicado: (2023)

SUN-575 Anabolic Steroids Induced Hyperthyroidism
por: Aljaberi, Asma, et al.
Publicado: (2019)

575 Are There Racial Disparities in Burn Center Care?
por: Bessey, Palmer Q, et al.
Publicado: (2022)

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
por: Agius, Mark A, et al.
Publicado: (2017)

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer
por: COHN, ALLEN, et al.
Publicado: (2014)

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
por: Annunziata, Christina M., et al.
Publicado: (2012)

Art, ciéncia i medi natural.
Publicado: (1994)

Medie and Info-pubmed: 2010 update
por: Ohta, Tomoko, et al.
Publicado: (2010)

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
por: Denlinger, Crystal S., et al.
Publicado: (2021)

Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
por: Narwal, Rajesh, et al.
Publicado: (2013)

MediVisión 3.2 para Windows.

Chocolate in History: Food, Medicine, Medi-Food
por: Lippi, Donatella
Publicado: (2013)

Medical thoracoscopy for tuberculous pleurisy: A retrospective analysis of 575 cases
por: Zhao, Tingting, et al.
Publicado: (2019)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
por: Domachowske, Joseph B, et al.
Publicado: (2017)

MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer
por: Greer, Yoshimi Endo, et al.
Publicado: (2019)

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
por: Lassen, U, et al.
Publicado: (2012)

Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells
por: Wu, Erxi, et al.
Publicado: (2008)

Challenging the Cost Effectiveness of Medi-Cal Managed Care
por: Riner, R. Myles
Publicado: (2009)

Targeting CD73 in the tumor microenvironment with MEDI9447
por: Hay, Carl M., et al.
Publicado: (2016)

PDGFR-β(+) fibroblasts deteriorate survival in human solid tumors: a meta-analysis
por: Hu, Guoming, et al.
Publicado: (2021)

Accuracy of ED Bedside Ultrasound for Identification of gallstones: retrospective analysis of 575 studies
por: Scruggs, William, et al.
Publicado: (2008)

Run 575 MD - 75.03.10: Vacuum experiment in Sector 21
por: Fischer, E
Publicado: (1975)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
por: Frentzas, Sophia, et al.
Publicado: (2023)

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
por: Mo, Gary, et al.
Publicado: (2017)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease
por: Calverley, Peter M. A., et al.
Publicado: (2017)

PDGFRβ regulates craniofacial development through homodimers and functional heterodimers with PDGFRα
por: Fantauzzo, Katherine A., et al.
Publicado: (2016)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

Improving interMediAte Risk management. MARK study
por: Martí, Ruth, et al.
Publicado: (2011)

Financial Performance and Participation in Medicaid and Medi-Cal Managed Care
por: McCue, Michael J., et al.
Publicado: (2001)

MediDial cards: a quick win for service improvement
por: Davies, Mike, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b9v78qau461k8a8apr8nl1q9hb